New treatment modalities are rare in pharma R&D, but Vertex Pharmaceuticals Inc. has joined the buzz surrounding the development of novel medicines targeting protein degradation by linking up with Kymera Therapeutics Inc. to discover small-molecule protein degraders for use against multiple diseases.
Vertex Targeting Protein Degradation In $1bn Kymera Deal
Vertex and Kymera will use insights into the ubiquitin-proteasome pathway, for sending unwanted proteins off to recycling, to discover new drug candidates.
More from Deals
More from Business
• By
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.